1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 1,500 | 1,740 | 16:30 |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 13:26 | Laekna partners with Lilly to develop obesity therapy | 3 | Pharmaceutical Business Review | ||
| 03:17 | LAEKNA-B Last Leapfrogs 7%+ after Announcing Shr Placing on 48% Rally Ytd | 1 | AASTOCKS | ||
| 02:47 | LAEKNA-B Places Shrs at 15%+ Discount to Raise $230M Net Proceeds | 1 | AASTOCKS | ||
| LAEKNA Aktie jetzt für 0€ handeln | |||||
| 01:13 | LAEKNA-B (02105): PLACING OF NEW SHARES UNDER GENERAL MANDATE | 2 | HKEx | ||
| Mi | China-based biotech Laekna teams up with Lilly to develop muscle preserving obesity drug | 9 | Reuters | ||
| Mi | LAEKNA-B Once Leaps ~40% After Signing Clinical Collaboration Agreement with Lilly for Obesity Drug | 8 | AASTOCKS | ||
| Mi | listed Laekna hits 10-month peak on Eli Lilly deal | 8 | Reuters | ||
| Mi | LAEKNA-B (02105): VOLUNTARY ANNOUNCEMENT CLINICAL COLLABORATION WITH LILLY ON LAE102 IN THE U.S. FOR THE TREATMENT OF OBESITY | 2 | HKEx | ||
| 18.10. | LAEKNA-B (02105): POLL RESULTS OF THE EXTRAORDINARY GENERAL MEETING HELD ON 18 OCTOBER 2024 | 2 | HKEx | ||
| 18.10. | LAEKNA-B (02105): VOLUNTARY ANNOUNCEMENT SUBCUTANEOUS COHORT INITIATED IN PHASE I CLINICAL TRIAL OF LAE102 FOR THE TREATMENT OF OBESITY | 2 | HKEx | ||
| 27.09. | LAEKNA-B (02105): NOTICE OF EXTRAORDINARY GENERAL MEETING | - | HKEx | ||
| 27.09. | LAEKNA-B (02105): PROXY FORM FOR THE EXTRAORDINARY GENERAL MEETING | - | HKEx | ||
| 27.09. | LAEKNA-B (02105): (1) PROPOSED GRANT OF RSUS TO DIRECTORS UNDER THE 2024 SHARE AWARD SCHEME; AND (2) NOTICE OF EXTRAORDINARY GENERAL MEETING | 3 | HKEx | ||
| 05.09. | LAEKNA-B (02105): GRANT OF RESTRICTED SHARE UNITS | - | HKEx | ||
| 26.08. | LAEKNA-B (02105): INTERIM REPORT 2024 | - | HKEx | ||
| 16.08. | LAEKNA-B (02105): INTERIM RESULTS ANNOUNCEMENT FOR THE SIX MONTHS ENDED JUNE 30, 2024 | 1 | HKEx | ||
| 06.08. | LAEKNA-B (02105): DATE OF BOARD MEETING | 1 | HKEx | ||
| 26.06. | LAEKNA-B (02105): VOLUNTARY ANNOUNCEMENT FIRST SUBJECT DOSED IN PHASE I CLINICAL TRIAL OF LAE102 FOR THE TREATMENT OF OBESITY | 1 | HKEx | ||
| 14.06. | LAEKNA-B (02105): POLL RESULTS OF THE ANNUAL GENERAL MEETING HELD ON 14 JUNE 2024 | - | HKEx | ||
| 30.05. | LAEKNA-B (02105): 2024 SHARE AWARD SCHEME | - | HKEx |
Seite:
1 2 Weiter >>
24 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIONTECH | 98,35 | +0,77 % | BioNTech-Aktie: Was bringt diese Übernahme? | Die BioNTech-Aktie hat am Mittwoch um fast +5% auf 111,48 US$ zugelegt, nachdem die Mainzer eine insgesamt fast eine Milliarde US$ schwere Übernahme bekannt gegeben haben. Was steckt hinter diesem Deal?... ► Artikel lesen | |
| VIKING THERAPEUTICS | 48,760 | -0,33 % | Viking Therapeutics Garners Analyst Support For NASH And Metabolic Programs | ||
| GENMAB | 194,45 | +0,46 % | Genmab A/S (GMAB): Among 12 High Growth Large Cap Stocks to Buy Now | ||
| SAREPTA THERAPEUTICS | 105,00 | -0,24 % | Sarepta Therapeutics, Inc. (SRPT): Among 12 High Growth Large Cap Stocks to Buy Now | ||
| NEUROCRINE BIOSCIENCES | 116,40 | -0,56 % | Neurocrine Biosciences Aktie: Vertrauen der Investoren gewinnen! | Die Neurocrine Biosciences Aktie verzeichnete am 9. November 2024 einen bemerkenswerten Kursanstieg von 1,42% und schloss bei 125,74 USD. Dieser Zuwachs setzt den positiven Trend der letzten Wochen... ► Artikel lesen | |
| HALOZYME THERAPEUTICS | 42,940 | -1,13 % | PMorgan: JPMORGAN stuft HALOZYME THERAPEUTICS INC auf 'Neutral' | NEW YORK (dpa-AFX Analyser) - Die US-Bank JPMorgan hat die Einstufung für Halozyme angesichts des Interesses an Evotec auf "Neutral" mit einem Kursziel von 54 US-Dollar belassen. Analystin Jessica Fye... ► Artikel lesen | |
| IMMUNITYBIO | 4,731 | +2,27 % | ImmunityBio geht Partnerschaft mit nCartes zur Optimierung klinischer Studien ein | ||
| ABCELLERA BIOLOGICS | 2,501 | -1,46 % | AbCellera Reports Q2 2024 Business Results | VANCOUVER, British Columbia--(BUSINESS WIRE)--AbCellera (Nasdaq: ABCL) today announced financial results for the second quarter of 2024. All financial information in this press release is reported... ► Artikel lesen | |
| OXFORD NANOPORE TECHNOLOGIES | 1,486 | -2,11 % | Oxford Nanopore Technologies: Oxford Nanopore Announces Landmark UK Government Partnership to Advance Genomics-Driven Healthcare Innovation in the UK | New strategic partnership between UK Biobank, Genomics England, NHS England and Oxford Nanopore designed to: Advance biomedical research and translate discoveries for improved patient... ► Artikel lesen | |
| VOYAGER THERAPEUTICS | 5,160 | +1,38 % | Voyager Therapeutics stock hits 52-week low at $5.71 | ||
| ALKERMES | 26,200 | 0,00 % | Alkermes, DaVita, Jabil, Ralph Lauren, among potential M&A candidates - BofA | ||
| APPLIED THERAPEUTICS | 8,835 | -4,49 % | Pre-market Movers: Portage Biotech, Veea, Intuitive Machines, Applied Therapeutics, Galmed Pharmaceuticals | BEIJING (dpa-AFX) - The following are some of the stocks making big moves in Wednesday's pre-market trading (as of 08.30 A.M. ET).In the Green Portage Biotech Inc. (PRTG) is up over 179% at... ► Artikel lesen | |
| SCHOLAR ROCK | 26,400 | 0,00 % | Scholar Rock Reports Third Quarter 2024 Financial Results and Highlights Business Progress | CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK), a late-stage biopharmaceutical company focused on advancing innovative treatments for spinal muscular atrophy (SMA), cardiometabolic... ► Artikel lesen | |
| QUANTUM-SI | 1,230 | -12,14 % | Quantum-Si Shares Slip After Next-Gen Proteomics Platforms Are Unveiled | ||
| CARIBOU BIOSCIENCES | 1,955 | -0,26 % | Caribou Biosciences, Inc.: Caribou Biosciences Appoints Tina Albertson, MD, PhD, as Chief Medical Officer | -- Highly-experienced hematologist and oncologist with proven track record successfully driving global clinical development of CAR-T cell therapies -- BERKELEY, Calif., Aug. 12, 2024 (GLOBE NEWSWIRE)... ► Artikel lesen |
LAEKNA INC gehört der Branche Biotechnologie an. Die relative Kursveränderung beträgt aktuell 0,00 % bei einem Aktienkurs von 1,190 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu LAEKNA INC finden Sie auf Wallstreet Online.
